Equities analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings of $0.56 per share for the current quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.43 to $0.68. Teva Pharmaceutical Industries posted earnings per share of $0.93 in the same quarter last year, which indicates a negative year-over-year growth rate of 39.8%. The firm is expected to announce its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.93 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $3.03. For the next fiscal year, analysts forecast that the firm will post earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.11. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. Teva Pharmaceutical Industries’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 EPS.
A number of equities research analysts have commented on the company. Bank of America upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating and set a $16.12 target price on the stock in a report on Thursday, January 3rd. ValuEngine cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Credit Suisse Group set a $26.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 13th. Zacks Investment Research upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Monday, December 3rd. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, November 7th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $22.15.
In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total value of $25,795.10. Following the transaction, the vice president now directly owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 2,922 shares of company stock worth $53,962 over the last ninety days. Corporate insiders own 0.43% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Rehmann Capital Advisory Group raised its position in shares of Teva Pharmaceutical Industries by 8.8% in the 3rd quarter. Rehmann Capital Advisory Group now owns 9,814 shares of the company’s stock worth $211,000 after buying an additional 795 shares during the period. Daiwa Securities Group Inc. raised its position in Teva Pharmaceutical Industries by 7.3% in the third quarter. Daiwa Securities Group Inc. now owns 34,183 shares of the company’s stock valued at $736,000 after purchasing an additional 2,329 shares during the period. Bridgewater Associates LP raised its position in Teva Pharmaceutical Industries by 11.3% in the third quarter. Bridgewater Associates LP now owns 23,600 shares of the company’s stock valued at $508,000 after purchasing an additional 2,400 shares during the period. HPM Partners LLC raised its position in Teva Pharmaceutical Industries by 25.4% in the second quarter. HPM Partners LLC now owns 14,657 shares of the company’s stock valued at $356,000 after purchasing an additional 2,971 shares during the period. Finally, Virginia Retirement Systems ET AL raised its position in Teva Pharmaceutical Industries by 6.7% in the third quarter. Virginia Retirement Systems ET AL now owns 55,600 shares of the company’s stock valued at $1,198,000 after purchasing an additional 3,500 shares during the period. 61.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:TEVA opened at $18.45 on Friday. The firm has a market cap of $18.26 billion, a price-to-earnings ratio of 4.69, a P/E/G ratio of 5.71 and a beta of 1.10. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. Teva Pharmaceutical Industries has a one year low of $14.59 and a one year high of $25.96.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: What is a Stop Order?
Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.